Latest filings (excl ownership)
15-12G
Securities registration termination
21 Mar 24
EFFECT
Notice of effectiveness
13 Mar 24
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
12 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Mar 24
POS AM
Prospectus update (post-effective amendment)
12 Mar 24
25
Voluntary exchange delisting
11 Mar 24
8-K
LianBio Announces Completion of Strategic Review
13 Feb 24
8-K
Entry into a Material Definitive Agreement
26 Dec 23
8-K
LianBio Announces Departure of Chief Financial Officer
20 Dec 23
8-K
LianBio Announces Departure of Chief Executive Officer
19 Dec 23
8-K
Regulation FD Disclosure
6 Dec 23
8-K
Other Events
1 Dec 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 23
8-K
LianBio Announces Topline Results from Phase 3 LIBRA Trial of
30 Oct 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
14 Aug 23
UPLOAD
Letter from SEC
24 Jul 23
CORRESP
Correspondence with SEC
20 Jul 23
UPLOAD
Letter from SEC
10 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
23 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update
11 May 23
8-K
Regulation FD Disclosure
1 May 23
EFFECT
Notice of effectiveness
28 Apr 23
S-3/A
Shelf registration (amended)
26 Apr 23
8-K
LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients
26 Apr 23
CORRESP
Correspondence with SEC
26 Apr 23
8-K
Other Events
21 Apr 23
DEFA14A
Additional proxy soliciting materials
19 Apr 23
DEF 14A
Definitive proxy
19 Apr 23
S-3/A
Shelf registration (amended)
28 Mar 23
S-8
Registration of securities for employees
28 Mar 23
10-K
2022 FY
Annual report
28 Mar 23
CORRESP
Correspondence with SEC
28 Mar 23
8-K
LianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
27 Mar 23
8-K
Departure of Directors or Certain Officers
17 Mar 23
UPLOAD
Letter from SEC
22 Dec 22
Latest ownership filings
4
Ehong Gu
11 Apr 24
SC 13D/A
PERCEPTIVE ADVISORS LLC
29 Feb 24
4
Konstantin Poukalov
20 Feb 24
4
JOSEPH EDELMAN
20 Feb 24
4
Adam Leo Stone
20 Feb 24
4
ANASTASIOS GIANAKAKOS
20 Feb 24
4
Susan Michele Silbermann
20 Feb 24
144
Notice of proposed sale of securities
8 Jan 24
144
Notice of proposed sale of securities
29 Dec 23
3
Ehong Gu
26 Dec 23
SC 13D
TANG CAPITAL PARTNERS LP
30 Nov 23
SC 13G
TANG CAPITAL PARTNERS LP
1 Nov 23
4
Wei Wei Chen
23 Jun 23
4
ANASTASIOS GIANAKAKOS
23 Jun 23
4
Susan Michele Silbermann
23 Jun 23
4
Adam Leo Stone
23 Jun 23
4
Konstantin Poukalov
23 Jun 23
4
JOSEPH EDELMAN
23 Jun 23
4
Brianne Jahn
31 Mar 23
4
JIANG QIAN
31 Mar 23
4
Yizhe Wang
31 Mar 23
4
Yi Larson
31 Mar 23
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 23
4
Yi Larson
24 Jan 23
4
Brianne Jahn
24 Jan 23
4
JIANG QIAN
24 Jan 23
4
Yizhe Wang
24 Jan 23
4
JIANG QIAN
5 Jan 23
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Nov 22
4
JOSEPH EDELMAN
22 Aug 22
4
JOSEPH EDELMAN
27 Jun 22
4
Konstantin Poukalov
27 Jun 22
4
Adam Leo Stone
27 Jun 22
4
ANASTASIOS GIANAKAKOS
27 Jun 22
4
Susan Michele Silbermann
27 Jun 22
4
JOSEPH EDELMAN
27 May 22
4
JOSEPH EDELMAN
25 May 22
4
Debra Yu
6 May 22
4
Wei Wei Chen
8 Apr 22
3
Wei Wei Chen
8 Apr 22